While Rallybio Corp has overperformed by 2.58%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, RLYB fell by -57.69%, with highs and lows ranging from $1.54 to $0.22, whereas the simple moving average fell by -43.87% in the last 200 days.
On April 09, 2025, H.C. Wainwright Downgraded Rallybio Corp (NASDAQ: RLYB) to Neutral. A report published by JP Morgan on May 15, 2024, Downgraded its rating to ‘Neutral’ for RLYB. Jefferies also Downgraded RLYB shares as ‘Hold’, setting a target price of $1.50 on the company’s shares in a report dated February 07, 2024. H.C. Wainwright Initiated an Buy rating on April 17, 2023, and assigned a price target of $18. Wedbush initiated its ‘Outperform’ rating for RLYB, as published in its report on April 10, 2023. JP Morgan’s report from December 09, 2022 suggests a price prediction of $21 for RLYB shares, giving the stock a ‘Overweight’ rating. JMP Securities also rated the stock as ‘Mkt Outperform’.
Analysis of Rallybio Corp (RLYB)
There are several well-rounded types of analysis and research techniques that can be used to gain a clear view of Rallybio Corp’s future performance, with equity being one of the most critical indicators. The goal here is to ensure that your current return on equity of -67.28% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 14.68, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
As an indicator of volatility for any stock, average volume can also be very valuable, and RLYB is recording an average volume of 2.75M. On a monthly basis, the volatility of the stock is set at 13.97%, whereas on a weekly basis, it is put at 23.95%, with a gain of 22.09% over the past seven days. Furthermore, long-term investors anticipate a median target price of $1.00, showing growth from the present price of $0.41, which can serve as yet another indication of whether RLYB is worth investing in or should be passed over.
How Do You Analyze Rallybio Corp Shares?
Apart from looking at the fundamentals, you should also pay attention to the number of company employees who own shares. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 52.22%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 29.12% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
RLYB shares are owned by institutional investors to the tune of 29.12% at present.
